Low prevalence of antiretroviral resistance among persons recently infected with human immunodeficiency virus in two US cities

International Journal of STD and AIDS

Volumn 13, Issue 8, 2002, Pages 554-558

  Sullivan, P S ^a   Buskin, S E ^b   Turner, J H ^c   Cheingsong, R ^d   Saekhou, A ^d   Kalish, M L ^d   Jones, J L ^a   Respess, R ^d   Kovacs, A ^e   Heneine, W ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^c Los Angeles Department of Public Health   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e Dept of Physics   (United States)

Author keywords

Genotypic testing; HIV; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; UNITED STATES; VIRUS MUTATION;

ADOLESCENT; ADULT; AGED; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LOS ANGELES; MALE; MIDDLE AGED; MUTATION; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WASHINGTON;

EID: 0036312392     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646202760159684     Document Type: Article

References (14)

1. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
2. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
3. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
4. Using CD4 counts to evaluate the stages and epidemiology of HIV infection in South Carolina public clinic patients
5. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
6. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998
7. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
8. Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States
9. Discrimination of subtype B and non-subtype B strains of human immunodeficiency virus type 1 by serotyping: Correlation with genotyping
10. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus
11. HIV-1 drug resistance in newly infected individuals
12. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy naïve HIV-1 infected US military personnel
13. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
14. HIV drug resistance and viral fitness